Profil bibliographique

Y. Abdou

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

8Publications signalées

1Citations signalées

2Affiliations récentes

Les institutions déclarées

University of North Carolina at Chapel Hill Carolina Institute for NanoMedicine

Les domaines associés

Advanced Breast Cancer TherapiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesBRCA gene mutations in cancer

Les publications récentes

Accès ouvert 2026 article OpenAlex

424RO SACI-IO HR+: Final results from a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC)

A.C. Garrido-Castro, T. Li, S.E. Kim, J. Desrosiers et autres

us (code pays fourni par la source)

0 citations ESMO Open

2026 conference-abstract OpenAlex

Abstract PS4-03-12: Quantifyher (trial in progress): quantitative immunofluorescence and/or messenger rna to measure her2 expression in patients with metastatic breast cancer treated with trastuzumab deruxtecan (tbcrc066)

E. P. Taranto, W. Fawn, C. Desirae, E. Walinsky et autres

us (code pays fourni par la source)

0 citations Clinical Cancer Research

2026 conference-abstract OpenAlex

Abstract PS5-08-28: Phase I pilot of pegylated liposomal doxorubicin, CD40 agonist antibody CDX-1140, and Flt3 ligand CDX-301 in advanced HER2-negative breast cancer

S. M. Reddy, C. A. Santa-Maria, N. Chen, V. Kaklamani et autres

us (code pays fourni par la source)

0 citations Clinical Cancer Research

2026 conference-abstract OpenAlex

Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

G. Gupta, A. Y. Ho, Faeze Gharibpoor, Y. Abdou et autres

us (code pays fourni par la source)

1 citation Clinical Cancer Research

2026 conference-abstract OpenAlex

Abstract PS2-06-28: Clinicogenomic and Immune Profiles of Male Breast Cancer by Race: Insights from a Large Real-World Cohort

Y. Abdou, Ellen Jaeger, S. Fragkogianni, E. S. Williams et autres

us (code pays fourni par la source)

0 citations Clinical Cancer Research

2026 conference-abstract OpenAlex

Abstract PS5-09-04: Tbcrc 058: a randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (nct06099769)

R. Nanda, Y. Chen, Y. Abdou, N. Jahan et autres

us, gb (code pays fourni par la source)

0 citations Clinical Cancer Research

2026 conference-abstract OpenAlex

Abstract PS4-09-24: Clinical and economic impact of the 21-gene assay for guiding treatment in patients with HR+/HER2- early breast cancer across racial and ethnic subgroups in the US

G. Cuyun Carter, C. Moyon, V. Berdunov, M. Gouldson et autres

us, gb (code pays fourni par la source)

0 citations Clinical Cancer Research

2026 conference-abstract OpenAlex

Abstract PS2-07-15: Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC061

J. M. Balko, P. I. Gonzalez-Ericsson, Brandie Taylor, Andres A. Ocampo et autres

us (code pays fourni par la source)

0 citations Clinical Cancer Research

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.